Wynn Capital LLC Purchases New Shares in Abbott Laboratories (NYSE:ABT)

Wynn Capital LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 3,329 shares of the healthcare product maker’s stock, valued at approximately $366,000.

A number of other large investors have also added to or reduced their stakes in the company. Rise Advisors LLC acquired a new position in Abbott Laboratories during the 4th quarter worth $37,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $40,000. Cornerstone Planning Group LLC boosted its holdings in shares of Abbott Laboratories by 79.4% in the 3rd quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after buying an additional 201 shares during the period. Legacy Financial Group LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $46,000. Finally, Briaud Financial Planning Inc acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $48,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at $9,444,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the sale, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,435 shares of company stock valued at $6,451,298. 0.47% of the stock is owned by corporate insiders.

Abbott Laboratories Trading Down 0.7 %

Shares of NYSE:ABT traded down $0.70 during mid-day trading on Wednesday, reaching $106.89. The stock had a trading volume of 5,050,066 shares, compared to its average volume of 5,719,627. The firm has a market cap of $185.47 billion, a PE ratio of 33.51, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74. The firm has a 50 day simple moving average of $114.00 and a two-hundred day simple moving average of $107.97. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. Abbott Laboratories has a twelve month low of $89.67 and a twelve month high of $121.64.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. The business had revenue of $9.96 billion for the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. Abbott Laboratories’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period last year, the company posted $1.03 EPS. On average, research analysts predict that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a $0.55 dividend. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a dividend yield of 2.06%. Abbott Laboratories’s dividend payout ratio is presently 68.54%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ABT shares. Barclays reduced their target price on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday. Raymond James reiterated a “buy” rating and issued a $124.00 target price on shares of Abbott Laboratories in a report on Wednesday. Citigroup boosted their target price on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada dropped their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, April 18th. Finally, Evercore ISI boosted their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $121.50.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.